Immunoscintigraphy of colon cancers with the human monoclonal antibody COU-1. 1994

H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
Department of Medical Microbiology, Odense University, Denmark.

The human monoclonal immunoglobulin M (IgM) antibody, COU-1 is obtained from a human-human hybridoma, which is derived by fusion between a human B-lymphoblastoid cell line and lymphocytes obtained from mesenteric lymph nodes from a patient with colorectal cancer. COU-1 recognizes a 43 kilodaltons intracellularly located cytokeratin-like protein, strongly expressed by adenocarcinoma tissue as compared to normal tissues. In tumor-bearing nude mice, antibody COU-1 labeled with 125I has been shown to accumulate in human colon cancer grafts when compared to human melanoma grafts and the normal mouse tissues. The observed accumulation was sufficient to be detected externally by immunoscintigraphy. Antigen-binding fragments of the antibody were also prepared and were shown to accumulate in colon cancer grafts. Improved tumor to normal tissue ratio was seen with the half-monomeric fragment, and the time required was reduced. In the clinic, five patients with suspected colorectal cancer were given 2 mg of 131I-labeled COU-1. No adverse effects were detected in any of the patients. Planar images were obtained on days 1, 2, 3, 5, and 7 after administration. The best images were obtained on days 5 and 7. Tumors were localized by immunoscintigraphy in four of the patients. Of these patients, surgery revealed that three of them had primary colorectal cancers located in the cecum, the ascending colon, and the rectum, respectively, while one patient had a pancreatic cancer. The smallest lesion observed had a diameter of 3 cm. In one of the patients, otherwise undiagnosed multiple liver metastases were revealed by the immunoscintigraphy and confirmed at surgery. An x-ray of the colon performed on the fifth patient had shown a stricture in the descending colon suspected to be caused by cancer. The tumor scintigraphy showed no accumulation of the antibody. Surgery revealed that the stricture was caused by adherence and not cancer. These findings are encouraging for further studies of this human monoclonal antibody in cancer patients.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D007128 Immunoglobulin Fragments Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques. Antibody Fragment,Antibody Fragments,Ig Fragment,Ig Fragments,Immunoglobulin Fragment,Fragment, Antibody,Fragment, Ig,Fragment, Immunoglobulin,Fragments, Antibody,Fragments, Ig,Fragments, Immunoglobulin
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D016719 Radioimmunodetection Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera. Immunoscintigraphy, Radiolabeled,Radioimmunoimaging,Radioimmunoscintigraphy,Immunoscintigraphy, Radiolabelled,Radiolabeled Immunoscintigraphy,Radiolabelled Immunoscintigraphy,Immunoscintigraphies, Radiolabeled,Immunoscintigraphies, Radiolabelled,Radioimmunodetections,Radioimmunoimagings,Radioimmunoscintigraphies,Radiolabeled Immunoscintigraphies,Radiolabelled Immunoscintigraphies

Related Publications

H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
April 1986, The Tohoku journal of experimental medicine,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
February 1994, Journal of the Royal College of Surgeons of Edinburgh,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
October 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
October 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
April 1992, American journal of surgery,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
February 1992, Annals of nuclear medicine,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
January 2001, Anticancer research,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
January 1987, The Japanese journal of surgery,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
January 2006, Hepato-gastroenterology,
H Ditzel, and J W Rasmussen, and P Borup-Christensen, and K Erb, and J C Jensenius
May 1984, Behring Institute Mitteilungen,
Copied contents to your clipboard!